Batoclimab vs Placebo for Generalized Myasthenia Gravis: A Randomized Clinical Trial.,JAMA Neurology

当前位置： X-MOL 学术 › JAMA Neurol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Batoclimab vs Placebo for Generalized Myasthenia Gravis: A Randomized Clinical Trial.
JAMA Neurology ( IF 29.0 ) Pub Date : 2024-03-04 , DOI: 10.1001/jamaneurol.2024.0044
Chong Yan ₁ , Yaoxian Yue ₂ , Yuzhou Guan ₃ , Bitao Bu ₄ , Qing Ke ₅ , Ruisheng Duan ₆ , Hui Deng ₇ , Qun Xue ₈ , Haishan Jiang ₉ , Fei Xiao ₁₀ , Huan Yang ₁₁ , Ting Chang ₁₂ , Zhangyu Zou ₁₃ , Haifeng Li ₁₄ , Song Tan ₁₅ , Haibing Xiao ₁₆ , Hongyu Zhou ₁₇ , Hua Zhang ₁₈ , Qiang Meng ₁₉ , Wenyu Li ₂₀ , Wei Li ₂₁ , Junhong Guo ₂₂ , Yali Zhang ₂₃ , Zunbo Li ₂₄ , Jianglong Tu ₂₅ , Jianquan Shi ₂₆ , Wei Li ₂₇ , Michael Lee ₂₈ , Yu Chen ₂₈ , Xiaolu Tao ₂₈ , Shuai Zhao ₂₈ , Ping Li ₂₈ , Chongbo Zhao ₁ , Jianying Xi ₂₉ , Chuanzhu Yan ₂₉ , Bin Zhang ₂₉ , Min Song ₂₉ , Rui Zheng ₂₉ , Xiaojun Ding ₂₉ , Cuiping Zhao ₂₉ , Ying Tan ₂₉ , Jiayu Shi ₂₉ , Jianwen Wang ₂₉ , Xiaoli Li ₂₉ , Bing Yang ₂₉ , Min Zhang ₂₉ , Congcong Wang ₂₉ , Xu Wang ₂₉ , Xingyi Xiao ₂₉ , Xiaopei Ji ₂₉ , Hui Zheng ₂₉ , Jing Luo ₂₉ , Hao Zhou ₂₉ , Huanhuan Li ₂₉ , Zhe Ruan ₂₉ , Lidong Jiao ₂₉ , Hui Lu ₂₉ , Jialin Chen ₂₉ , Sheng Chen ₂₉ , Hongbin Sun ₂₉ , Quantao Zeng ₂₉ , Yan Xie ₂₉ , Kai Chen ₂₉ , Li Zeng ₂₉ , Wenshuang Zeng ₂₉ , Qin Du ₂₉ , Jian Yin ₂₉ , Shifang Hou ₂₉ , Lei Zhang ₂₉ , Mingming Zhao ₂₉ , Ruihan Yang ₂₉ , Wenjiao Huang ₂₉ , Xingyue Hu ₂₉ , Luya Jin ₂₉ , Yuying Zhao ₂₉ , Tingjun Dai ₂₉ , Wei Zhang ₂₉ , Xueli Chang ₂₉ , Xue Bai ₂₉ , Xiuyun Li ₂₉ , Jia Fu ₂₉ , Ting Xiong ₂₉ , Jiaojiao Ma ₂₉ , Hongdong Zhao ₂₉ , Meng Zhang ₂₉ , Jun Dong ₂₉ ,

Affiliation

National Center for Neurological Disorders, Huashan Rare Disease Centre, Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China
Department of Neurology, Qilu Hospital (Qingdao), Shandong University, Qingdao, China
Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Department of Neurology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
Department of Neurology, the First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Ji’nan, China
Department of Neurology and Neuroscience Center, the First Hospital of Jilin University, Changchun, China
Department of Neurology, the First Affiliated Hospital of Soochow University, Suzhou, China
Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China
Department of Neurology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China
Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
Department of Neurology, Tangdu Hospital, the Fourth Military Medical University, Xi’an, China
Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China
Department of Neurology, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
Neuromedicine Center, Department of Neurology, The University of Hong Kong—Shenzhen Hospital, Shenzhen, China
Department of Neurology, West China Hospital, Sichuan University, Chengdu, China
Department of Neurology, Beijing Hospital, Beijing, China
Department of Neurology, the First People’s Hospital of Yunnan Province & the Affiliated Hospital of Kunming University of Science and Technology, Kunming, China
Department of Neurology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Department of Neurology, Qilu Hospital, Shandong University, Ji’nan, China
Department of Neurology, First Hospital, Shanxi Medical University, Taiyuan, China
Department of Neurology, Chifeng Municipal Hospital, Chifeng, China
Department of Neurology, Xi’an Gaoxin Hospital, Xi’an Medical College, Xi’an, China
Department of Neurology, the Second Affiliated Hospital of Nanchang University, Nanchang, China
Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
Department of Neurology, Army Medical Center of PLA, Army Medical University, Chongqing, China
Nona Biosciences (Suzhou) Co Ltd, Shanghai, China
for the Batoclimab Study Team

Myasthenia gravis (MG) is caused by autoantibodies that disrupt the neuromuscular junction. The neonatal fragment crystallizable receptor (FcRn) antagonists, efgartigimod and rozanolixizumab, reduce immunoglobulin G (IgG) level in the circulation and alleviate symptoms in patients with generalized MG.

中文翻译：

Batoclimab 与安慰剂治疗全身性重症肌无力：一项随机临床试验。

重症肌无力 (MG) 是由破坏神经肌肉接头的自身抗体引起的。新生儿片段可结晶受体 (FcRn) 拮抗剂 efgartigimod 和 rozanolixizumab 可降低循环中的免疫球蛋白 G (IgG) 水平，缓解全身性 MG 患者的症状。

更新日期：2024-03-04

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>